Compositions and methods for enhancing discriminatory RNA interference

• US 20070259827A1
• Filed: 01/25/2007
• Published: 11/08/2007
• Est. Priority Date: 01/25/2006
• Status: Abandoned Application

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Aronin, Neil, Zamore, Phillip, Schwarz, Dianne
• Application Number:
  US11/698,689
• Publication Number:
  US 20070259827A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/331 Universal or degenerate base
• CPC Class Codes: C12N 2320/50 Methods for regulating/modulating their activity
• CPC Class Codes: C12Y 115/01001 Superoxide dismutase (1.15.1.1)

Abstract

The present invention provides methods for enhancing discriminatory RNA silencing by RNA silencing agents. In particular, the invention provides methods for generating RNA silencing agents which can discriminate between target and non-target mRNAs that differ in sequence by only one nucleotide. Also provided are improved RNA silencing agents with enhanced discriminatory RNA silencing, e.g., single nucleotide discriminatory RNA silencing. The compositions and methods of the invention are useful in therapeutic strategies for treating genetic disorders associated with dominant, gain-of-function gene mutations.

Claims

1. A method of enhancing discriminatory RNA silencing by an RNA silencing agent comprising positioning a specificity-determining nucleotide of said agent at a nucleotide position within an antisense strand of said agent, wherein the nucleotide position is 3′

of the seed sequence of said antisense strand, such that discriminatory RNA silencing is enhanced.

2. The method of claim 1, wherein the specificity-determining nucleotide forms a mismatched or wobble base pair with a non-target mRNA.

3. The method of claim 2, wherein the mismatched base-pair is a purine:

purine mismatch.

4. The method of claim 3, wherein the purine mismatch is a G:

G mismatch.

5. The method of claim 1, wherein the specificity-determining nucleotide forms a Watson-Crick base pair with a target mRNA.

6. The method of claim 1 or 4, wherein the nucleotide position is selected from the group consisting of P9, P10, P12, P13, P14, P15, P16 and P19, and wherein said nucleotide position is relative to the 5′

end of the antisense strand.

7. The method of claim 6, wherein the nucleotide position is P10.

8. The method of claim 6, wherein the nucleotide position is P16.

9. The method of claim 1, wherein discriminatory RNA silencing by the RNA silencing agent is further enhanced by substituting at least one nucleotide within the antisense strand with a destabilizing nucleotide.

10. The method of claim 9, wherein the destabilizing nucleotide is a universal base.

11. The method of claim 10, wherein the universal base is inosine or 2′

-deoxyinosine.

12. The method of claim 9, wherein the destabilizing nucleotide is position within 5 nucleotide positions of the specificity-determining nucleotide.

13. The method of claim 2, wherein the non-target RNA is encoded by a wild-type allele corresponding to the mutant allele of a gene encoding a mutant gain-of-function protein.

14. The method of claim 5, wherein the specificity-determining nucleotide forms a Watson-Crick base pair with a single-nucleotide polymorphism associated with a mutant allele of a gene encoding a mutant gain-of-function protein.

15. The method of claim 13 or 14, wherein said mutant gain-of-function protein is a mutant SOD1 or Hungtingtin protein.

16. The method of claim 1, wherein the RNA silencing agent is a siRNA.

17. The method of claim 1, wherein the RNA silencing agent provides more than 4-fold discrimination between two alleles which differ by at least one nucleotide.

18. An RNA silencing agent synthesized according the method of claim 1.

32. The method of claim 6, wherein the nucleotide position is P16.

39. A method of treating a subject having a disease or disorder correlated with the presence of a dominant gain of function mutant allele, the method comprising administering to the subject a therapeutically effective amount of an RNA silencing agent synthesized according to the method of claim 1 or 19.

40. The method of claim 39, wherein the disease is a neurodegenerative disease.

41. The method of claim 40, wherein the neurodegenerative disease is selected from the group of amyotrophic lateral sclerosis, Huntington'"'"'s disease, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, and spinocerebellar ataxia (SCA).

19. A method of enhancing discriminatory RNA silencing by an RNA silencing agent comprising substituting at least one nucleotide within an antisense strand of said agent with a destabilizing nucleotide, such that discriminatory RNA silencing by said RNA silencing agent is enhanced.

20. The method of claim 19, wherein the antisense strand has a G/C content of greater than 40%.

21. The method of claim 19, wherein the RNA silencing agent is capable of inducing the discriminatory RNA silencing of a target sequence having a G/C content of greater than 40%.

22. The method of claim 19, wherein the melting temperature (Tm) of a duplex formed by said antisense strand and a corresponding target mRNA sequence is decreased.

23. The method of claim 22, wherein the Tm is decreased by more than 0.5°

C.

24. The method of claim 22, wherein the Tm is decreased by less than 2°

C.

25. The method of claim 19, wherein the destabilizing nucleotide is a universal base.

26. The method of claim 19, wherein the universal base is selected from the group consisting of inosine and 2′

-deoxyinosine.

27. The method of claim 19, wherein the nucleotide with the antisense strand is a G or C.

28. The method of claim 19, wherein the destabilizing nucleotide forms a base pair with a C in the target sequence.

29. The method of claim 19, wherein discriminatory RNA silencing by the RNA silencing agent is further enhanced by positioning a specificity-determining nucleotide of said agent at a nucleotide position within the antisense strand of said agent, wherein the nucleotide position is 3′

of the seed sequence of said antisense strand.

30. The method of claim 29, wherein the nucleotide position is selected from the group consisting of P9, P10, P12, P13, P14, P15, P16 and P19, and wherein said nucleotide position is relative to the 5′

end of the antisense strand.

31. The method of claim 30, wherein the nucleotide position is P10.

33. The method of method of claim 19 or 29, wherein the destabilizing nucleotide is present at a position within 5 nucleotides of the specificity-determining nucleotide.

34. The method of claim 19, wherein the RNA silencing agent is capable of substantially silencing a mutant allele of a gain-of-function protein without substantially silencing a corresponding wild-type allele.

35. The method of claim 19, wherein a specificity-determining nucleotide of the RNA silencing agent forms a Watson-Crick base pair with a single-nucleotide polymorphism associated with a mutant allele of a gene encoding a mutant gain-of-function protein.

36. The method of claim 34 or 35, wherein said mutant gain-of-function protein is a mutant SOD1 or Hungtingtin protein.

37. The method of claim 19, wherein the RNA silencing agent provides more than 4-fold discrimination between two alleles which differ by at least one nucleotide.

38. An RNA silencing agent synthesized according the method of claim 19.

42. A method of enhancing discriminatory RNA silencing by an RNA silencing agent comprising positioning a specificity-determining nucleotide of said agent at nucleotide position P10 or P 16 relative to the 5′

end of an antisense strand of said agent, wherein (i) the nucleotide position is 3′

of the seed sequence of said antisense strand, (ii) the specificity-determining nucleotide forms a purine;

purine mismatch with a non-target mRNA; and

(iii) the specificity-determining nucleotide forms a Watson-Crick base pair with a target mRNA, such that discriminatory RNA silencing is enhanced.